DOTA-CXCR4-L

DOTA-CXCR4-L is a CXCR4 targeting peptide. DOTA-CXCR4-L can be used in the study of cancers, including glioblastoma and triple-negative breast cancer. NODAGA-LM3 can be labeled with [68Ga]/[177Lu] for the synthesis/research of Radionuclide-Drug Conjugates (RDCs) [1].

Product Specifications

UNSPSC

12352209

Target

CXCR; Radionuclide-Drug Conjugates (RDCs)

Type

Peptides

Related Pathways

Antibody-drug Conjugate/ADC Related; GPCR/G Protein; Immunology/Inflammation

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/dota-cxcr4-l.html

Solubility

10 mM in DMSO

Smiles

O=C(N[C@H]1CC2=CC3=C(C=C2)C=CC=C3)[C@H](CCCNC(N)=N)NC([C@@H](CCCNC(C4=CN=C(C=C4)NNC(CN5CCN(CCN(CCN(CC5)CC(O)=O)CC(O)=O)CC(O)=O)=O)=O)N(C)C([C@@H](CC6=CC=C(O)C=C6)NC(CNC1=O)=O)=O)=O

Molecular Formula

C58H78N16O14

Molecular Weight

1223.34

References & Citations

[1]Luna-Gutiérrez M, et al. Preclinical evaluation of the theranostic 68 Ga/177 Lu-[DOTA-CXCR4-L] pair [C]//Trends in Radiopharmaceuticals (ISTR-2019) . Proceedings of an International Symposium. Programme and Abstracts. 2020.